Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 19 (4), 637-41

Hepatolithiasis Associated With Cholangiocarcinoma

Affiliations

Hepatolithiasis Associated With Cholangiocarcinoma

S Kubo et al. World J Surg.

Abstract

Hepatolithiasis is a risk factor for cholangiocarcinoma. It is difficult to make an accurate diagnosis before treatment. In a retrospective study, we identified characteristic clinical features of 103 patients with hepatolithiasis (group H) and 10 patients with hepatolithiasis associated with cholangiocarcinoma (group HC), and examined the methods for diagnosis and treatment. The main symptoms were abdominal pain, fever, and jaundice, although few patients in group HC had jaundice. The incidence of abnormal serum levels of carcinoembryonic antigen (CEA) in group HC was higher than in group H. The incidence of cholangiocarcinoma in cases in which most of the stones were present in the intrahepatic ducts of the left lobe (type I-L) was higher than the incidence in the other patients. Of the patients who underwent portography in group HC, portal veins in the portion of the liver containing the cholangiocarcinoma were not seen, and this region was atrophic in the operative specimens. The incidence of portal obstruction in portograms in group HC was higher than that in group H. The possibility of carcinoma should be kept in mind if there are high levels of CEA, if the location of the stones is classified as type I-L, or if portal veins cannot be seen on portograms. In such patients, liver resection should be considered because there may be undiagnosed cholangiocarcinoma.

Similar articles

See all similar articles

Cited by 41 PubMed Central articles

See all "Cited by" articles

References

    1. Am J Pathol. 1942 Jul;18(4):675-87 - PubMed
    1. World J Surg. 1986 Apr;10(2):287-93 - PubMed
    1. Virchows Arch A Pathol Anat Histopathol. 1985;406(1):45-58 - PubMed
    1. J Clin Gastroenterol. 1984 Dec;6(6):539-47 - PubMed
    1. Cancer. 1985 Jun 15;55(12 ):2826-9 - PubMed

Substances

LinkOut - more resources

Feedback